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INTRODUCTION
Hepatocellular carcinoma (HCC) constitutes one of the most 
common gastrointestinal malignancies worldwide, and its in-
cidence continues to increase.1 The historical role of radiation 
therapy (RT) in HCC patients has been insignificant due to the 
low radiation tolerance of the whole liver. However, radiother-
apeutic technical advances using three-dimensional confor-
mal RT (3D-CRT), intensity-modulated RT (IMRT) and image-
guided RT (IGRT) technology have considerably contributed 
to the improvement of therapeutic ratios in terms of the ad-
ministration of higher radiation doses to the target volumes 
and significant reduction in surrounding normal tissue com-
plications.1-3
In locally-advanced–stage HCC, the frequency of uncon-
trolled primary tumors after previous irradiation or sustained 
symptomatic local problems remains high. Thus, RT currently 
plays an important role in locally-advanced as well as early-
stage, locally-confined liver tumors. The need for re-irradiation 
as a salvage option in HCC patients is also continuously in-
creasing. 
Despite the development of modern RT technology, re-irra-
diation in HCC remains a challenging issue due to the relative-
ly low radiation tolerance of the small and large bowels and the 
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continuous target motion around the diaphragm or normal 
bowels.4,5 Another remaining problem for re-irradiation is the 
strong necessity of an accurate tool for determining radiation 
dose summation. Fortunately, commercially available software 
that applies an intensity-based free-form deformable registra-
tion algorithm has been utilized at several institutions recent-
ly.6-8 Therefore, conceptually, we can perform re-irradiation 
more safely than before by using a more conformal treatment 
planning method involving a novel RT technique and by more 
accurately estimating cumulative radiation doses using a de-
formable image registration (DIR) tool.
In the present study, we sought to evaluate the potential clini-
cal applicability of the DIR method in HCC re-irradiation by 
analyzing the dosimetric results, clinical outcomes, and toxici-
ties of re-irradiation cases. Based on the study results, we sug-
gest future perspectives on re-irradiation for HCC using DIR.
MATERIALS AND METHODS
Patient population
Between August 2010 and March 2012, 12 eligible patients re-
ceived re-irradiation for HCC using helical tomotherapy (HT)-
based IMRT and were included in this study. We obtained the 
approval of the Institutional Review Board of Severance Hospi-
tal to conduct this study. The eligibility criteria of the study 
were as follows: re-irradiation using HT in HCC; re-irradiation 
delivery of full tolerable RT doses with normal tissue con-
straints; re-irradiation interval of more than 5 months from the 
first course of RT; and adequate hepatic function and general 
performance status allowing toleration of the entire RT course. 
Patients who received additional small doses of RT with 3D-
CRT or HT, which was regarded as boost RT for persistent dis-
eases, within 1–3 months after the first course of irradiation 
were excluded from this analysis.
Radiotherapy
Simulation of 3D-CRT was routinely performed in the same 
manner, in the supine position. To assess the respiration-asso-
ciated margins, fluoroscopic examination was regularly con-
ducted before 2011. Four-dimensional computed tomography 
(4D-CT) was introduced after 2011 and has been commonly 
used to evaluate the movement of the targets using a SO-
MATOM (Siemens, Berlin, Germany) CT scanner.
Prior to 2012, simulation of HT was performed using only 
the BodyFix system (Medical Intelligence, GmbH, Schwab-
munchen, Germany) to immobilize the patients, and the up-
per-abdominal area was compressed by elastic foils using low 
negative pressure in order to restrict body motion. Beyond that 
period, abdominal compressors, which directly compress the 
upper-abdominal areas below the xiphoid process, were uti-
lized with the BodyFix system to minimize the respiration-as-
sociated margins.
During HT, the simultaneous integrated boost (SIB) tech-
nique, which prescribes different fractional doses in gross tu-
mor volume (GTV) and clinical target volume (CTV), was 
commonly utilized. During re-irradiation, we were commonly 
confronted with problems of overdose in organs-at-risk 
(OARs); this was countered by routine adaptive planning, 
which reduced the treatment of target volumes after tumor 
shrinkage or reduced planning target volume (PTV) margins 
in close proximity to the critical organs.
Prescribed dose summation constraints for OARs were as 
follows: ≤50 Gy per 2 cc of small and large bowels; ≤45 Gy per 2 
cc of duodenum and stomach; and mean remaining liver dose 
(MRLD) ≤30 Gy, with at least 700 cc of remaining liver volume. 
However, when we were unable to comply with those dose 
constraints, we endeavored to prescribe the lowest doses pos-
sible to the OARs.
Target volume and critical organ assessment
OARs were slightly different according to the location of tu-
mors. For example, re-irradiation was relatively safe in tumors 
located around the liver dome or right lobe, and the liver itself 
was the main dose-limiting organ. In contrast, the neighboring 
bowels, duodenum, or stomach were the dose-limiting OARs 
in tumors located in the left lobe or lower portion of the liver. 
The purpose of this study was to re-evaluate the dosimetric 
summation results in critical organs; thus, we assessed the do-
simetric factors of the most important OARs for re-irradiation 
including the liver, bowels, duodenum, and stomach.
The dosimetric data were retrospectively retrieved from ac-
tual registered treatment records. At the time of re-irradiation, 
we could only approximately estimate the cumulative dose of 
critical organ using the Pinnacle (Philips, Madison, WI, USA) 
RT planning system. Each contoured organ was recalled to the 
software, and the OARs were newly contoured if needed. The 
VRL was defined as the total liver volume (VTL) minus CTV. CTV 
was defined as the treated GTV plus a margin of 0.3–0.5 cm. 
Bowels were defined as the total bowels including the small 
and large bowels, which were shown in the planning CT.
Deformable image registration method
DIR was performed using the software MIMvista version 5.2 
(MIM Software, Inc., Cleveland, OH, USA), which utilizes an 
intensity-based, free-form deformable registration algorithm. 
We chose the chronological dose summation scenario for this 
study, as this method reflected the latest information about 
each anatomical structure and was considered to be more reli-
able than the anti-chronological version. In the registration 
process, we the adjustment of important OARs was given pri-
ority. Deformed prescribed doses were summed with the dos-
es of the re-irradiation plan in the same manner as previously 
described.8 Dose summation was performed by both rigid 
(uniform transformation of all voxels) and deformable (de-
formable transformation based on voxel similarity) registration 
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methods. RT dose levels were evaluated on dose-volume histo-
grams. To evaluate the detailed dosimetric analyses, the cumu-
lative Dmax (ΣDmax), D0.1 cc (ΣD0.1 cc), D1 cc (ΣD1 cc), and D2 cc (ΣD2 cc) 
in each OAR were calculated. Dx cc was defined as the RT dose re-
ceiving X cc.
Evaluation of clinical outcome and toxicity 
Follow-up was regularly conducted after 1 month initially and 
then at 3- to 6-month intervals. Complete blood counts, liver 
function tests, and other important blood chemistry tests were 
performed every 1 to 2 weeks or more frequently during treat-
ment, and at 1-, 3-, and 6-month intervals thereafter.
To evaluate the treatment response, modified RECIST 
(mRECIST) criteria and RECIST criteria were utilized for HCC 
parenchymal lesions and abdominal lymph nodes (LNs), re-
spectively.9 Evaluation of major treatment responses was con-
ducted for in-field lesions. The timing of the response achieve-
ment was recorded as the earliest period of maximal tumor 
response, which was evaluated by the aforementioned criteria. 
Change in liver function was assessed based on the Child-
Pugh (C-P) classification. We hypothesized that major liver 
function change after RT could occur within early periods, and 
we evaluated the change in the C-P score for up to 6 months 
after each course of RT. In this study, we aimed to determine 
the safety of re-irradiation, and severe toxicity (≥grade 3) was 
evaluated. The criteria of toxicity were evaluated using the 
Common Toxicity Criteria for Adverse Events (CTCAE) version 4.
Statistical analyses
All statistical analyses were conducted using PASW statistics 18 
(SPSS Inc., Chicago, IL, USA). A non-parametric Wilcoxon 
rank-sum test was utilized to discriminate the difference be-
tween the two different types of dose summation methods (rig-
id vs. deformable). Fisher’s exact test was used to compare the 
distribution of variables. A p-value <0.05 was considered to be 
statistically significant, and all statistical analyses were based 
on the two-sided test.
RESULTS
Patient and treatment characteristics 
The patient characteristics at the first course of RT and at re-ir-
radiation are summarized in Table 1 and 2, respectively. The 
first course of RT was delivered by 3D-CRT (n=9) or HT (n=3). 
Concurrent chemotherapy (5-FU) was employed with RT in 
five patients, and nine patients received transarterial chemo-
embolization (TACE), doxorubicin-eluting bead TACE (DC-
bead TACE) or transarterial chemoinfusion (TACI) as com-
bined treatment modalities. Before the first course of RT, the 
majority of the patients (11 of 12) had received other localized 
or systemic treatments. The median primary prescribed total 
RT dose and daily fractional dose were 50 Gy (range, 36–60 Gy) 
and 1.8 Gy (range, 1.8–3 Gy), respectively. Re-irradiation was 
performed with a median total dose of 50 Gy (range, 36–58.42 
Gy) and a median fractional dose of 2.54 Gy (range, 2.5–9 Gy). 
The median elapsed time from the first course of RT to re-irra-
diation was 20.3 months (range, 5.3–69.4 months). Most of the 
re-irradiation fields were previously irradiated or were mar-
ginal areas in relation to the initial course of RT.
After re-irradiation, three patients (patients 1, 4, and 5) re-
ceived sorafenib for suspicious remnant lesions, and one pa-
tient (patient 2) received 5-FU-based systemic chemotherapy 
after extrahepatic disease progression. One patient (patient 10) 
received ten cycles of TACI after re-irradiation.
Therapeutic effect of RT
Treatment responses after the first irradiation and re-irradia-
tion are described in Table 1 and 4, respectively. In-field tumor 
response [complete response (CR)/partial response (PR)/sta-
ble disease (SD)] rates after the first and second courses of RT 
were 100% and 90.9%, respectively. One patient (patient 4) 
showed disease progression 3 months after re-irradiation, and 
we were unable to evaluate a response from one patient (pa-
tient 3) due to death before response assessment.
Dose summation indices for the liver
Table 3 shows the results of liver volume and liver dose sum-
mation indices.
The median VTL and the median VRL at the initial course of 
RT were 1531.1 cc (range, 1107.8–3041.3 cc) and 1131 cc (range, 
986.3–1560.9 cc), respectively. The median VTL and the VRL at 
the time of re-irradiation were 1157.8 cc (range, 887.9–2078.9 
cc) and 964.5 cc (range, 746.6–1335.7 cc), respectively. The me-
dian ΣMRLD for rigid- and deformable-type registration were 
28.3 Gy (range, 17.4–48.2 Gy) and 27.7 Gy (range, 17.2–42.7 Gy), 
respectively, and the results for the two different DIR methods 
did now show statistical difference (p=0.248, Wilcoxon rank-
sum test). In patients who showed a large change in VTL (Δ-VTL) 
between time intervals (patients 4, 5, 8, and 11), the MRLD 
(Δ-MRLD) indices of the two different DIR methods also showed 
a large difference.
In patients 4 and 11, the calculated ΣMRLD was overestimated 
compared to each course of MRLD due to a large CTV at the ini-
tial course and large differences in CTV between each course 
of RT. In this situation, the calculated ΣMRLD could be overesti-
mated compared to its predicted value, and a separate assess-
ment of MRLD in each course was mandatory. In patient 10, VTL 
and VRL in the initial course did not show a large difference as 
the main target was the portocaval LN.
Dose summation indices for other OARs
We assessed the usefulness of DIR methods by dosimetric cal-
culation and visual review. We visually inspected whether the 
Dmax points were actually in the predicted areas for each OAR. 
The actual Dmax dose summation results (initial Dmax+re-irradi-
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ation Dmax) from each course of RT were compared to the sum-
mated dose (ΣDmax) calculated by MIMvista. Among 36 avail-
able indices for OARs (bowel, duodenum, and stomach doses 
in each patient) dose summation (Table 4), 12 indices (33.3%) 
were useful for utilizing DIR, and 21 (58.3%) were useless. The 
remaining three indices (8.3%) showed contradictory results 
(different results for rigid and deformable types). There was no 
statistical difference between the two different DIR methods 
(rigid and deformable types) in terms of ΣD0.1 cc, ΣD1 cc, ΣD2 cc, 
and ΣDmax for each OAR.
A representative illustrative case (patient 4) is shown in Fig. 1.
Toxicity and evaluation of a causal relationship 
Liver function change as determined by C-P classification was 
observed in four and eight patients at the first and second 
courses of RT, respectively. Deterioration of liver function was 
found in two patients at the first course of RT (patients 4 and 5) 
(Table 1); however, this change was only a minor worsening of 
the C-P score. We also observed two patients who showed 
mild C-P score recovery. After re-irradiation, the majority of 
patients (6 of 12) showed deterioration of liver function, and 
severe worsening of liver function (C-P score elevation ≥3 
points) was also observed in four patients (patients 3, 4, 6, and 
9) (Table 5). In patients 3, 4, and 6, the causes of deaths were 
lung, liver abscess, and pleural effusion (patient 3), hepatore-
nal syndrome and hepatic failure (patient 4), and liver function 
deterioration and related superimposed septic shock (patient 
6). Among four patients who presented with a C-P score eleva-
tion ≥3 points, only one patient (patient 4) showed a high de-
formable ΣMRLD index of 42.7 Gy. A C-P score elevation ≥2 
points tended to be significantly associated with the use of 
TACE or DC-bead TACE as a combined treatment modality at 
re-irradiation (p=0.061, Fisher’s exact test). The median value 
of deformable ΣMRLD was not significantly associated with se-
vere C-P score elevation (ΣMRLD in patients with C-P score ele-
vation: ≥2 vs. <2, p=0.415; ΣMRLD in patients with C-P score ele-
vation: ≥3 vs. <3, p=0.465).
Patient 1 was diagnosed with gastric and duodenal ulcers 4 
months before re-irradiation and was treated for Helicobacter 
pylori eradication. However, duodenal ulcer perforation sud-
denly developed 20 months after re-irradiation and was man-
aged by emergency operation. The patient’s duodenal ΣDmax 
and ΣD0.1 cc by deformable type DIR were 70.7 Gy and 68.4 Gy, 
respectively.
DISCUSSION
The present study evaluated the feasibility of using a DIR meth-
od in the re-irradiation of HCC. Several publications reported 
the clinical utility of DIR algorithms in the head and neck re-
gions.6-8 This method uses a deformation map of vector fields 
by connecting each voxel from the initial CT to the second Ta
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course of CT. By assigning manually-contoured structures and 
planned RT doses to the corresponding voxels, DIR can be 
used to correct the time- and spatially-dependent distribution 
differences.10 Clinical application of this algorithm has been 
evaluated, and the acceptable error rates in consistency and re-
producibility have been demonstrated in head and neck areas.7 
However, in the study by Brock, et al.,11 the accuracy results from 
one anatomical site did not translate to another site, particular-
ly in the abdominal organs. A three-dimensional deformable 
phantom study performed by Juang, et al.12 also showed signifi-
cant errors in dose mapping using commercially available de-
formable registration algorithms.
Dosimetric study in the abdomen using this tool has not yet 
been reported. This is probably due to the unique features of 
uncertainty in abdominal areas, characterized by continuous 
movement of target volumes caused by normal bowel motion 
and respiration. Therefore, we could not convincingly demon-
strate that our dose summation method using DIR was rational 
or could be used practically in these highly variable regions. 
However, we hypothesized that OARs-centered DIR may per-
form better than not using any dose summation engines in the 
re-irradiation setting in terms of dose summation calculation. 
In addition, we were frequently confronted with challenging 
re-irradiation cases of HCC in the clinic and needed to exam-
ine the dosimetric analyses using this tool, which was the main 
purpose of this pilot study. All recruited patients had been re-
irradiated using HT, and commercially available DIR software 
was utilized to represent dose summation indices.
Re-irradiation in HCC was mainly administered as the last 
salvage option when the tumor was localized and there were 
no other possible treatment modalities. Despite re-irradiation 
dose limits to the in-field area, full tolerable doses were em-
ployed, and the overall response rate of 90.9% was encourag-
ing; moreover, PR could be achieved in three patients (27.3%) 
in our study. However, one duodenal perforation and four cas-
es of severe C-P score elevation developed.
When planning the treatment, we attempted to preserve the 
MRLD based on the critical volume model of liver.13 Liver func-
tion significantly deteriorated after re-irradiation at a relatively 
high frequency, whereas an evident causal dose-response was 
not identified. The consecutive employment of other combined 
treatments (TACE and DC-bead TACE) at re-irradiation was 
the main contributing factor for the development of severe liv-
er function damage. This was probably due to the extensive 
liver damage caused by TACE, which could be aggravated by 
vascular injuries that were already formed at the first course of 
irradiation. One case of duodenal ulcer perforation was identi-
fied; however, that patient already had a history of duodenal 
and gastric ulcers before re-irradiation, and ΣDmax and ΣD0.1 cc 
indices by deformable-type DIR were much higher than the 
tolerable doses. Bae, et al.14 reported the clinical importance of 
ulcer history in the development of severe duodenal toxicity 
following gastrointestinal stereotactic body radiotherapy, and 
the results were concordant with our experience.
In terms of intestinal OAR doses, we endeavored to adhere 
to normal tissue constraints in re-irradiation using stepwise 
adaptive planning. Although there were several patients who 
received significant cumulative doses in limited volumes of 
OARs, we did not observe clinically significant toxicities in all 
but one of these patients. However, the follow-up duration was 
limited, and additional follow-up in good performance future 
cohorts is needed to confirm the results.
In modern DIR calculations, different registration methods 
(rigid vs. deformable) did not show statistically different results 
in terms of dose summation for either solid (liver) or hollow 
(bowels, duodenum, stomach) OARs. However, when Δ-VTL 
was large between intervals, the Δ-MRLD between the two dif-
ferent types of DIR also seemed to increase. In hollow OARs, 
the dose summation using DIR revealed somewhat variable 
results, with 58.3% being useless. Moreover, visual inspections 
Table 5. Treatment Outcome after Re-Irradiation 
Pt Re-RT tumor response
Toxicity 
Last status
Liver C-P score change Gastrointestinal toxicity (≥grade 3)
1 Liver-CR/PVTT-PR (7 mo) A (6) → A (5): 3 mo Duodenal ulcer perforation: 20 mo Alive (31.3 mo)
2 PR (5 mo) A (5) → B (7): 6 mo Alive (21 mo)
3 N/A B (7) → C (10): 1.5 mo Death (1.6 mo)
4 PD (3 mo) A (6) → B (9): 1 mo → C (10): 3 mo Death (6.6 mo)
5 Liver-SD/PVTT-SD (1 mo) Death (15.4 mo)
6 SD (1 mo) B (7) → B (8): 1 mo → C (10): 3 mo Death (5 mo)
7 SD (6 mo) Alive (13.6 mo)
8 PR (6 mo) Alive (11.8 mo)
9 SD (1 mo) A (5) → A (6): 3 mo → C (10): 5 mo Alive (8.4 mo)
10 Liver-SD/PVTT-SD (3 mo) A (5) → A (6): 3 mo → A (5): 6 mo Alive (13.8 mo)
11 SD (4 mo) Alive (7 mo)
12 Liver-SD/LN-SD (3 mo) A (5) → B (7): 1 mo Alive (7.7 mo)
Re-RT, re-irradiation; C-P, Child-Pugh; CR, complete response; PVTT, portal vein tumor thrombosis; PR, partial response; N/A, not available; PD, progressive dis-
ease; SD, stable disease; LN, lymph node.
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in each region were essential to confirming the summation re-
sults. Thus, the modern DIR method might be more reliably 
utilized in solid organs, which have a limited spatial difference 
between intervals in terms of summated dose calculation, af-
ter careful visual review.
We aimed to investigate the clinical correlation between nor-
mal tissue dose summation results and high-degree clinico-
functional deteriorations. Although we did not find a dosimet-
ric causal relationship, subclinical mucosal changes in OARs 
could be substantially high, as previously reported.15 Moreover, 
in cirrhotic HCC patients, the frequency of undetectable mu-
cosal changes was commonly noticed, and special concern is 
required in this population.15,16 More intensive review involv-
ing endoscopic exams will disclose the subclinical toxicities in 
future studies.
In conclusion, the OARs-based, DIR-based dose summation 
method can be utilized in re-irradiation of HCC patients after 
careful visual confirmation of high-risk regions. Although we 
Fig. 1. Illustrative case (patient 4). Contrast-enhanced axial computed tomography before the first course of radiation (A) and at re-irradiation (B). Recon-
structed isodose lines using deformable image registration (DIR) at the first (A-1) and second course of irradiation (B-1) are shown, as well as the axial (C) 
and coronal (C-1) dose summation results using DIR. Narrow arrows in (A) and (B) indicate the tumor extent and wide arrows in (C) indicate potential 
high-risk regions (bowels) at re-irradiation. 
A
B
C
A-1
B-1
C-1
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did not reach optimal and accurate dose summation results 
under the current algorithms and circumferential uncertain-
ties, we can conclude that more favorable gastrointestinal toxic-
ity profiles are expected with this modern technology. DIR may 
be more reliably used in solid organs with limited spatial differ-
ence between intervals in comparison to the hollow organs, in 
terms of accurate prediction of dose summation. A more opti-
mized adaptive plan using a highly conformal RT technique 
and appropriate use of DIR may enhance radiotherapeutic out-
comes in future HCC cohorts treated with re-irradiation.
REFERENCES
1. Feng M, Ben-Josef E. Radiation therapy for hepatocellular carci-
noma. Semin Radiat Oncol 2011;21:271-7.
2. Wang PM, Hsu WC, Chung NN, Chang FL, Fogliata A, Cozzi L. 
Radiation treatment with volumetric modulated arc therapy of 
hepatocellular carcinoma patients. Early clinical outcome and 
toxicity profile from a retrospective analysis of 138 patients. Radiat 
Oncol 2012;7:207.
3. Lee DS, Seong J. Radiotherapeutic options for hepatocellular car-
cinoma with portal vein tumor thrombosis. Liver Cancer 2014;3: 
18-30.
4. Abusaris H, Hoogeman M, Nuyttens JJ. Re-irradiation: outcome, 
cumulative dose and toxicity in patients retreated with stereotac-
tic radiotherapy in the abdominal or pelvic region. Technol Can-
cer Res Treat 2012;11:591-7.
5. Koom WS, Choi Y, Shim SJ, Cha J, Seong J, Kim NK, et al. Reirradia-
tion to the pelvis for recurrent rectal cancer. J Surg Oncol 2012;105: 
637-42.
6. Castadot P, Lee JA, Parraga A, Geets X, Macq B, Grégoire V. Com-
parison of 12 deformable registration strategies in adaptive radia-
tion therapy for the treatment of head and neck tumors. Radioth-
er Oncol 2008;89:1-12.
7. Kovalchuk N, Jalisi S, Subramaniam RM, Truong MT. Deformable 
registration of preoperative PET/CT with postoperative radiation 
therapy planning CT in head and neck cancer. Radiographics 2012; 
32:1329-41.
8. Olteanu LA, Madani I, De Neve W, Vercauteren T, De Gersem W. 
Evaluation of deformable image coregistration in adaptive dose 
painting by numbers for head-and-neck cancer. Int J Radiat On-
col Biol Phys 2012;83:696-703.
9. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, et 
al. Comparison of tumor response by Response Evaluation Crite-
ria in Solid Tumors (RECIST) and modified RECIST in patients 
treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 
118:147-56.
10. Senthi S, Griffioen GH, van Sörnsen de Koste JR, Slotman BJ, 
Senan S. Comparing rigid and deformable dose registration for 
high dose thoracic re-irradiation. Radiother Oncol 2013;106:323-6.
11. Brock KK; Deformable Registration Accuracy Consortium. Re-
sults of a multi-institution deformable registration accuracy study 
(MIDRAS). Int J Radiat Oncol Biol Phys 2010;76:583-96.
12. Juang T, Das S, Adamovics J, Benning R, Oldham M. On the need 
for comprehensive validation of deformable image registration, 
investigated with a novel 3-dimensional deformable dosimeter. Int 
J Radiat Oncol Biol Phys 2013;87:414-21.
13. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et 
al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 
2010;76(3 Suppl):S94-100.
14. Bae SH, Kim MS, Cho CK, Kang JK, Lee SY, Lee KN, et al. Predictor 
of severe gastroduodenal toxicity after stereotactic body radiother-
apy for abdominopelvic malignancies. Int J Radiat Oncol Biol 
Phys 2012;84:e469-74.
15. Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, et al. Gastrodu-
odenal complications after concurrent chemoradiation therapy 
in patients with hepatocellular carcinoma: endoscopic findings 
and risk factors. Int J Radiat Oncol Biol Phys 2011;81:1343-51.
16. Lee IJ, Kim JW, Han KH, Kim JK, Kim KS, Choi JS, et al. Concur-
rent chemoradiotherapy shows long-term survival after conver-
sion from locally advanced to resectable hepatocellular carcino-
ma. Yonsei Med J 2014;55:1489-97.
